An interventional study of localized heat therapy in Meibomian Gland Dysfunction (Disorder), sponsored by Sight Sciences, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Meibomian Gland Dysfunction with a site in United States — 7 open to participants now, 11 under way, none of them phase 3. Meibomian Gland Dysfunction · United States.
Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, this one is the 50th largest by enrollment of the 62 interventional ones that give a count, is one of 6 that started in 2026, is one of 43 with no phase, and was the 60th registered.
173 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.
Browse Meibomian Gland Dysfunction studies →7 of the 64 studies in Meibomian Gland Dysfunction with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
University of Alabama at Birmingham · Sites in United States
Ages 18+
University of California, Berkeley · Sites in United States
Ages 18+
University of Houston · Sites in United States
Ages 18+
Illinois College of Optometry · Sites in United States
Ages 6–18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 4 7
First in 2008; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 50 across 139 interventional studies indexed under Meibomian Gland Dysfunction.
Median enrollment 44 across the 62 interventional studies, 33 across the 2 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Sight Sciences, Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.
Sight Sciences, Inc. has 3 studies filed under Meibomian Gland Dysfunction — fewer than ten, so there is no comparison to draw.
7 of the studies in Meibomian Gland Dysfunction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07229001Illinois College of OptometryTreating Meibomian Gland Disease in a Pediatric Population | 2026-12-30 |
| NCT07939360Essilor InternationalEvaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction. | 2026-12-31 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).
This study will collect data to assess the clinical utility of the Warming Hold period. The TearCare MGX Warming hold is a 10-minute period beyond completion of the Core Therapy time that serves to preserve elevated temperature by outputting only enough energy to maintain heat at the lowest setting of the system. At the minimum warmth setting the SmartLid device surfaces provide a steady state temperature of 39.0°C.
This is a prospective, randomized, assessor-masked, single-center, non-significant risk (NSR) study. To reduce potential bias in the study, study staff performing the endpoint assessments will be masked. Subjects will also be masked as to group assignment.
In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).
TearCare procedures in this study will include an in-office eyelid debridement, 15-minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects will receive one in-office TearCare procedure at the Procedure Visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of:
Any of the following dry eye treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 minute thermal treatment with TearCare MGX followed by 10 minute warming hold
Device: localized heat therapy
15 minute thermal treatment with TearCare MGX without subsequent warming hold period
Device: localized heat therapy
Blink-assisted, open eye therapy. Heat (45 degrees C) applied for 15 minutes to the upper and lower eyelids, followed by manual expression of the meibomian glands.
Mean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS)
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1. \- Toothpaste 2. \- Cloudy 3. \- Clear The difference between eyes in the MGSS is the score for the right eye minus the score for the left eye. The mean is the arithmetic mean of this difference for all subjects.
Time frame: MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).
Mean Change From Screening Visit Baseline in MGSS - Right Eye
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The right eye was the first eye expressed post-procedure.
Time frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Mean Change From Screening Visit Baseline in MGSS - Left Eye
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The left eye was the second eye expressed post-procedure.
Time frame: MGSS is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye
The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.
Time frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye
The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.
Time frame: MGYAL is assessed at the Screening visit (Day -30 to -7) and at the Procedure visit (Day 0)
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye
The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.
Time frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and post-treatment at the Procedure visit (Day 0)
Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye
The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.
Time frame: MGYCL is assessed at the Screening visit (Day -30 to Day -7) and at the Procedure visit (Day 0)
Subject Comfort During Expression of Second Lid
Subject Comfort during expression of second lid is assessed following treatment using a subject completed Likert scale rating the relative comfort of eyelid gland expression for the first lid expressed versus the second.
Time frame: Subject Comfort during expression of second lid is assessed post-treatment at the Procedure visit (Day 0)
Ease of Expression
Ease of expression is assessed following treatment using a masked-assessor completed Likert scale rating the relative ease of eyelid gland expression for the first lid expressed versus the second.
Time frame: Ease of expression is assessed following treatment at the Procedure visit (Day 0)
Subjects were recruited for the study between March 17, 2026 and April 16, 2026 at a comprehensive ophthalmic/optometric practice in Brecksville, OH.
| Milestone | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Started | 11 | 10 |
| Completed | 11 | 10 |
| Not completed | 0 | 0 |
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1. \- Toothpaste 2. \- Cloudy 3. \- Clear The difference between eyes in the MGSS is the score for the right eye minus the score for the left eye. The mean is the arithmetic mean of this difference for all subjects.
| meibomian gland score | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Difference Between Eyes in Meibomian Gland Secretion Score (MGSS) | -0.4 ± 4.8 | 3.8 ± 4.6 |
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The right eye was the first eye expressed post-procedure.
| meibomian gland score | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in MGSS - Right Eye | 15.8 ± 6.5 | 15.3 ± 5.2 |
The Meibomian Gland Secretion Score (MGSS) grades the consistency of secretions from the meibomian glands. Fifteen meibomian glands in each of the lower eyelids were gently pressed and the secretions were scored on the scale below. Sum of the grade (0 - 3) for each of the 15 glands. Range for this score is 0-45. A higher number indicates more normal meibomian gland activity. Score Description of Secretion: 0 - Nothing 1 - Toothpaste 2 - Cloudy 3 - Clear The change from baseline in the MGSS is the score obtained following treatment at the procedure visit minus the score obtained for the same eye at the Screening visit. The mean is the arithmetic mean of this difference for all eyes. The left eye was the second eye expressed post-procedure.
| meibomian gland score | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in MGSS - Left Eye | 15.0 ± 3.9 | 10.9 ± 6.1 |
The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.
| number of glands with any liquid | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Right Eye | 7.8 ± 1.8 | 7.4 ± 2.5 |
The Meibomian glands yielding any liquid (MGYAL) is the number of glands in the lower eyelid secreting any liquid, (regardless of graded quality). The score can range from 0 (no glands secreting liquid), to 15 (all 15 glands with liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYAL at screening and the MGYAL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.
| number of glands with any liquid | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Any Liquid (MGYAL) - Left Eye | 7.6 ± 2.2 | 6.3 ± 2.8 |
The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The right eye was the first eye expressed post-procedure.
| number of glands with clear liquid | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Right Eye | 1.5 ± 2 | 1.7 ± 1 |
The Meibomian glands yielding clear liquid (MGYCL) is the number of glands in the lower eyelid secreting clear liquid. The score can range from 0 (no glands secreting clear liquid), to 15 (all 15 glands with clear liquid secreted). A higher score is better. The mean change from Screening visit baseline is the mean difference between the MGYCL at screening and the MGYCL post-procedure at the procedure visit. The left eye was the second eye expressed post-procedure.
| number of glands with clear liquid | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Mean Change From Screening Visit Baseline in Meibomian Glands Yielding Clear Liquid (MGYCL) - Left Eye | 0.7 ± 1 | 0.5 ± 1 |
Subject Comfort during expression of second lid is assessed following treatment using a subject completed Likert scale rating the relative comfort of eyelid gland expression for the first lid expressed versus the second.
| Participants | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Comfort much better for 1st eye than 2nd eye | 3 | 2 |
| Comfort somewhat better for 1st eye than 2nd eye | 0 | 2 |
| Neutral | 6 | 5 |
| Comfort somewhat better for 2nd eye than 1st eye | 0 | 0 |
| Comfort much better for 2nd eye than 1st eye | 2 | 1 |
Ease of expression is assessed following treatment using a masked-assessor completed Likert scale rating the relative ease of eyelid gland expression for the first lid expressed versus the second.
| Participants | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| Much easier for the first eye than for the second eye | 0 | 0 |
| Somewhat easier for the first eye than for the second eye | 1 | 3 |
| Neutral | 8 | 6 |
| Somewhat easier for the second eye than for the first eye | 2 | 1 |
| Much easier for the second eye than for the first eye | 0 | 0 |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TearCare MGX With Warming Hold | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| TearCare MGX Without Warming Hold | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold |
|---|---|---|
| erythemaSkin and subcutaneous tissue disorders | 0/11 | 1/10 |
| eyelid irritationSkin and subcutaneous tissue disorders | 0/11 | 1/10 |
| Age, Categorical(Participants) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 5 | 9 |
| >=65 years | 7 | 5 | 12 |
| Age, Continuous(years) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| Mean | 63.8 ± 16.1 | 63.5 ± 13.2 | 63.7 ± 14.4 |
| Sex: Female, Male(Participants) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 10 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 11 | 9 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| United States | 11 | 10 | 21 |
| Ocular Surface Disease Index (OSDI)(units on a scale) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| Mean | 35.4 ± 10.3 | 35.7 ± 15.9 | 35.6 ± 12.9 |
| Meibomian Gland Secretion Score (MGSS) - right eye(Meibomian Gland Secretion Score) | TearCare MGX With Warming Hold | TearCare MGX Without Warming Hold | Total |
|---|---|---|---|
| Mean | 7.5 ± 2.0 | 7.6 ± 2.6 | 7.5 ± 2.2 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Protection of patient confidentiality.
Ran from Mar 2026 to primary completion in May 2026, 2 months.
Results were first posted in Nov 2026, 5 months after primary completion.
Of 23 industry-sponsored interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 2 months is below that.
Counting every sponsor, half of 75 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sight Sciences, Inc.